Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival

Andrea Manni, Olof H. Pearson, James S. Marshall, Bahauddin M. Arafah

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Follow-up data of 113 patients with stage IV breast cancer treated with the antiestrogen tamoxifen show that the duration of remission is in average in excess of 21 months with a median of 16 months. Survival from start of antiestrogen therapy was significantly longer in patients who responded to tamoxifen, in those with dominant site of disease in the soft tissue, and in those with less extensive metastatic involvement. Overall survival from onset of metastasis was also much longer in patients who had responded to tamoxifen than in those who had failed (median of 52 and a half months vs 23 months). Hypophysectomy and androgen therapy used sequentially after antiestrogen each induced further remissions in almost half of the patients with a median duration of 16 months and 10 months respectively. Five drug chemotherapy used in most patients after maximum benefit had been obtained with endocrine therapy induced remissions in two-thirds of the patients with a median duration of 8 months. Adriamycin used sequentially as a single agent induced significant further palliation in almost half of the patients with a median duration of 4 and a half months. We conclude that sequential endocrine therapy and chemotherapy is highly effective in the treatment of stage IV breast cancer and offers prolonged survival to patients with hormone responsive tumors.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalBreast Cancer Research and Treatment
Volume1
Issue number2
DOIs
StatePublished - Jun 1 1981

Fingerprint

Breast Neoplasms
Drug Therapy
Survival
Estrogen Receptor Modulators
Tamoxifen
Therapeutics
Hypophysectomy
Doxorubicin
Androgens
Hormones
Neoplasm Metastasis
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Manni, Andrea ; Pearson, Olof H. ; Marshall, James S. ; Arafah, Bahauddin M. / Sequential endocrine therapy and chemotherapy in metastatic breast cancer : Effects on survival. In: Breast Cancer Research and Treatment. 1981 ; Vol. 1, No. 2. pp. 97-103.
@article{04d864ede4ae4b16be8f45163a087aae,
title = "Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival",
abstract = "Follow-up data of 113 patients with stage IV breast cancer treated with the antiestrogen tamoxifen show that the duration of remission is in average in excess of 21 months with a median of 16 months. Survival from start of antiestrogen therapy was significantly longer in patients who responded to tamoxifen, in those with dominant site of disease in the soft tissue, and in those with less extensive metastatic involvement. Overall survival from onset of metastasis was also much longer in patients who had responded to tamoxifen than in those who had failed (median of 52 and a half months vs 23 months). Hypophysectomy and androgen therapy used sequentially after antiestrogen each induced further remissions in almost half of the patients with a median duration of 16 months and 10 months respectively. Five drug chemotherapy used in most patients after maximum benefit had been obtained with endocrine therapy induced remissions in two-thirds of the patients with a median duration of 8 months. Adriamycin used sequentially as a single agent induced significant further palliation in almost half of the patients with a median duration of 4 and a half months. We conclude that sequential endocrine therapy and chemotherapy is highly effective in the treatment of stage IV breast cancer and offers prolonged survival to patients with hormone responsive tumors.",
author = "Andrea Manni and Pearson, {Olof H.} and Marshall, {James S.} and Arafah, {Bahauddin M.}",
year = "1981",
month = "6",
day = "1",
doi = "10.1007/BF01805861",
language = "English (US)",
volume = "1",
pages = "97--103",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

Sequential endocrine therapy and chemotherapy in metastatic breast cancer : Effects on survival. / Manni, Andrea; Pearson, Olof H.; Marshall, James S.; Arafah, Bahauddin M.

In: Breast Cancer Research and Treatment, Vol. 1, No. 2, 01.06.1981, p. 97-103.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sequential endocrine therapy and chemotherapy in metastatic breast cancer

T2 - Effects on survival

AU - Manni, Andrea

AU - Pearson, Olof H.

AU - Marshall, James S.

AU - Arafah, Bahauddin M.

PY - 1981/6/1

Y1 - 1981/6/1

N2 - Follow-up data of 113 patients with stage IV breast cancer treated with the antiestrogen tamoxifen show that the duration of remission is in average in excess of 21 months with a median of 16 months. Survival from start of antiestrogen therapy was significantly longer in patients who responded to tamoxifen, in those with dominant site of disease in the soft tissue, and in those with less extensive metastatic involvement. Overall survival from onset of metastasis was also much longer in patients who had responded to tamoxifen than in those who had failed (median of 52 and a half months vs 23 months). Hypophysectomy and androgen therapy used sequentially after antiestrogen each induced further remissions in almost half of the patients with a median duration of 16 months and 10 months respectively. Five drug chemotherapy used in most patients after maximum benefit had been obtained with endocrine therapy induced remissions in two-thirds of the patients with a median duration of 8 months. Adriamycin used sequentially as a single agent induced significant further palliation in almost half of the patients with a median duration of 4 and a half months. We conclude that sequential endocrine therapy and chemotherapy is highly effective in the treatment of stage IV breast cancer and offers prolonged survival to patients with hormone responsive tumors.

AB - Follow-up data of 113 patients with stage IV breast cancer treated with the antiestrogen tamoxifen show that the duration of remission is in average in excess of 21 months with a median of 16 months. Survival from start of antiestrogen therapy was significantly longer in patients who responded to tamoxifen, in those with dominant site of disease in the soft tissue, and in those with less extensive metastatic involvement. Overall survival from onset of metastasis was also much longer in patients who had responded to tamoxifen than in those who had failed (median of 52 and a half months vs 23 months). Hypophysectomy and androgen therapy used sequentially after antiestrogen each induced further remissions in almost half of the patients with a median duration of 16 months and 10 months respectively. Five drug chemotherapy used in most patients after maximum benefit had been obtained with endocrine therapy induced remissions in two-thirds of the patients with a median duration of 8 months. Adriamycin used sequentially as a single agent induced significant further palliation in almost half of the patients with a median duration of 4 and a half months. We conclude that sequential endocrine therapy and chemotherapy is highly effective in the treatment of stage IV breast cancer and offers prolonged survival to patients with hormone responsive tumors.

UR - http://www.scopus.com/inward/record.url?scp=0019804209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019804209&partnerID=8YFLogxK

U2 - 10.1007/BF01805861

DO - 10.1007/BF01805861

M3 - Article

C2 - 6184099

AN - SCOPUS:0019804209

VL - 1

SP - 97

EP - 103

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -